Company & Sponsor Intelligence
UCB Pharma
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials1
Recruiting0
Completed1
Countries1
Therapeutic footprint
epilepsy
Indexed studies
NCT00160654Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy
epilepsy · Hong KongPHASE4
epilepsy · Hong KongPHASE4
NCT00175929A Study of Brivaracetam in Subjects With Partial Onset Seizures
epilepsy · BelgiumPHASE2
epilepsy · BelgiumPHASE2
NCT00319605Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam
epilepsy · SpainCOMPLETED
epilepsy · SpainCOMPLETED
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →